Avantor (NYSE:AVTR) is betting on a structural overhaul to break a cycle of underperformance, unveiling its "Revival" transformation program alongside fourth-quarter results that showed persistent revenue pressure.
The Radnor, Pennsylvania-based life sciences supplier reported a GAAP net loss of $530 million for 2025, largely weighed down by a massive $785 million goodwill impairment charge recorded earlier in the year.
The company’s fourth-quarter net sales fell 1% to $1.66 billion, with organic sales sliding 4% as biopharma customers continued to tighten budgets.
Adjusted EBITDA for the quarter stood at $252 million, yielding an adjusted EPS of $0.22.
Management characterized 2026 as a "transition year," warning that aggressive investments in a brand relaunch and a $15 million digital e-commerce upgrade would be necessary before the top line restores its momentum.
Despite the GAAP loss, Avantor maintained a disciplined balance sheet, ending the year with adjusted net leverage of 3.2x and $1.07 billion in full-year adjusted EBITDA.